Frontiers in Cell and Developmental Biology (Jul 2024)
MicroRNA-21 in urologic cancers: from molecular mechanisms to clinical implications
- Lifeng Gan,
- Lifeng Gan,
- Lifeng Gan,
- Liying Zheng,
- Junrong Zou,
- Junrong Zou,
- Peiyue Luo,
- Peiyue Luo,
- Peiyue Luo,
- Tao Chen,
- Tao Chen,
- Tao Chen,
- Jun Zou,
- Jun Zou,
- Jun Zou,
- Wei Li,
- Wei Li,
- Wei Li,
- Qi Chen,
- Qi Chen,
- Qi Chen,
- Le Cheng,
- Le Cheng,
- Le Cheng,
- Fangtao Zhang,
- Fangtao Zhang,
- Fangtao Zhang,
- Biao Qian,
- Biao Qian
Affiliations
- Lifeng Gan
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Lifeng Gan
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Lifeng Gan
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Liying Zheng
- Department of Graduate, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Junrong Zou
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Junrong Zou
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Peiyue Luo
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Peiyue Luo
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Peiyue Luo
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Tao Chen
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Tao Chen
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Tao Chen
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Jun Zou
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Jun Zou
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Jun Zou
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Wei Li
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Wei Li
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Wei Li
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Qi Chen
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Qi Chen
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Qi Chen
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Le Cheng
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Le Cheng
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Le Cheng
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Fangtao Zhang
- The First Clinical College, Gannan Medical University, Ganzhou, Jiangxi, China
- Fangtao Zhang
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Fangtao Zhang
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- Biao Qian
- Department of Urology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, China
- Biao Qian
- Key Laboratory of Urology and Andrology of Ganzhou, Ganzhou, Jiangxi, China
- DOI
- https://doi.org/10.3389/fcell.2024.1437951
- Journal volume & issue
-
Vol. 12
Abstract
The three most common kinds of urologic malignancies are prostate, bladder, and kidney cancer, which typically cause substantial morbidity and mortality. Early detection and effective treatment are essential due to their high fatality rates. As a result, there is an urgent need for innovative research to improve the clinical management of patients with urologic cancers. A type of small noncoding RNAs of 22 nucleotides, microRNAs (miRNAs) are well-known for their important roles in a variety of developmental processes. Among these, microRNA-21 (miR-21) stands out as a commonly studied miRNA with implications in tumorigenesis and cancer development, particularly in urological tumors. Recent research has shed light on the dysregulation of miR-21 in urological tumors, offering insights into its potential as a prognostic, diagnostic, and therapeutic tool. This review delves into the pathogenesis of miR-21 in prostate, bladder, and renal cancers, its utility as a cancer biomarker, and the therapeutic possibilities of targeting miR-21.
Keywords
